Lv1
40 积分 2025-04-22 加入
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
20天前
已完结
Allogeneic CAR-T cell therapy in autoimmune diseases
1个月前
已完结
The landscape of cell and gene therapy today
1个月前
已完结
Current trends in exosomes as therapeutic drug delivery systems
1个月前
已完结
Cancer cell therapies: global clinical trial trends and emerging directions
1个月前
已完结
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
2个月前
已完结
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2个月前
已完结
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022
5个月前
已完结
CAR T cells produced in vivo to treat cardiac injury
5个月前
已完结
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
5个月前
已完结
皖公网安备34019202002308
